UPF
19.11.2020 12:54:08 CET | Business Wire | Press release
The Rally of Hope, the third organized by UPF, is expected to draw much international participation this weekend. This rally, produced in Korea, will focus mainly on the Korean peninsula, seventy years after the outbreak of the Korean war (1950-53). UPF is an NGO in general consultative status with the Economic and Social Council of the United Nations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005660/en/
Remembering yesterday’s war heroes; highlighting today’s peacemakers
In addition to featuring prominent global leaders, the renowned Little Angels Folk Ballet of Korea will perform a special tribute in honor of veterans of the Korean War.
Dr. Hak Ja Han Moon , the co-founder of UPF, will be keynote speaker. Her husband, the late Reverend Moon, was liberated by UN forces from the North Korean death camp of Heungnam. In her memoirs, Mother of Peace , Mrs. Moon explains how she escaped death several times during this conflict.
Further speakers include current and former heads of state and government whose countries were part of the United Nations forces in the Korean War: Sahle-Work Zewde , president of Ethiopia, the only current female head of State in Africa; Yves Leterme , Prime Minister of Belgium (2009-2011); Stephen Harper Prime Minister of Canada (2006-2015), now chairman of the International Democrat Union.
Other speakers include current heads of state whose countries have overcome domestic tensions and progressed toward national reconciliation: Salva Kiir , President of South Sudan, who recently invited the UPF chairman to attend the signing of the Juba peace agreement; Uhuru Kenyatta , President of Kenya and Mahinda Rajapaska , Prime Minister of Sri Lanka.
Mr. Jacques Marion , president of UPF Europe-Middle East, remarked that the Rally of Hope sets a strong signal for a peaceful unification. The interfaith prayer by religious leaders, the presence of Veterans of the Korean war representing the conflicting armies, will testify and sound an appeal for reconciliation on the divided peninsula, he said.
UPF states on its website that a main objective is the “peaceful reunification of the Korean peninsula and harmonious relations among the nations of Northeast Asia.” Directed towards this goal, UPF strives to realize the vision of a global democratic society, driven by the free-market and centered on family-based universal values.
This rally will be a dazzling display of digital technology from the land of K‑pop. A live internet audience of millions will be joined by an interactive audience using various social media apps.
Rally of Hope - Live Broadcast:
Date: November 22, 2020, 1:30 AM - 3:30 AM CET
Participants: VIPs & guests from all over the world (register at: rallyofhope.eu
)
Highlights of the Rally (Online):
November 22, 2020, 6:00 PM - 7:00 PM CET
Participants: VIPs & guests from all over Europe & Middle East
Public registration for the rally (live or highlights) at: rallyofhope.eu
Media direct live streaming will use: peacelink.live
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005660/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom